Oncolytic virus companies develop engineered or naturally occurring viruses that selectively infect and destroy cancer cells. These therapies can also stimulate anti-tumour immune responses, supporting their use alone or alongside other forms of cancer immunotherapy.
This category includes companies working on:
Browse 8 UK oncolytic virus companies below.
Viral vector platform for solid tumour immunotherapy
Akamis Bio is a clinical-stage oncology company developing oncolytic adenoviral therapeutics for solid tumours. Its platform delivers immunotherapeutic payloads directly to tumour sites following intravenous dosing, enabling tumour-localised expression of proteins including CD40 agonist antibodies and cytokines. Lead…
Oncolytic adenovirus therapeutics for solid tumour cancer treatment
PsiVac is a UK-based biotechnology company developing oncolytic virus therapeutics for the treatment of cancer. Its patented technology uses genetically modified adenoviruses engineered to selectively replicate within and destroy tumour cells while leaving healthy cells intact, while also stimulating the body's immune…
Systemic viral immunotherapy for solid tumours
Stratosvir develops engineered viral immunotherapies for advanced solid tumours and their metastases. Its platform aims to overcome the limitations of injecting therapeutic viruses directly into tumours by enabling systemic, intravenous delivery. Within tumour tissue, the viruses are designed to replicate selectively…
Oncolytic virus immunotherapies engineered to destroy solid tumours
Bioarchitech is a preclinical-stage biotechnology company developing oncolytic virus-based immunotherapies for the treatment of common solid tumours. The company engineers vaccinia virus to encode antibody-like immunotherapy molecules within the viral genome, enabling localised delivery of immune-activating payloads…
Oncolytic virus platform for tumour-targeted cancer immunotherapy
Accession Therapeutics is a clinical-stage biotechnology company developing tumour-targeted immunotherapies based on its proprietary oncolytic virus platform. Designed for systemic delivery, the platform selectively replicates within cancer cells to generate therapeutic payloads locally at the tumour site. The…
Clinical-stage developer of oncolytic immunotherapies for cancer treatment
Replimune is the UK research and development site of Replimune Group, a clinical-stage biotechnology company developing oncolytic immunotherapies for cancer. Its platform uses genetically engineered herpes simplex viruses to selectively replicate within and destroy tumour cells, releasing tumour antigens and…
Oncolytic viral therapies engineered for intravenous cancer treatment
Theolytics is a clinical-stage biotechnology company developing oncolytic viral therapies for cancer. Its phenotypic screening platform enables the discovery and development of adenovirus-based candidates optimised for intravenous delivery and specific patient populations. The lead programme, THEO-260, entered Phase…
Oncolytic vaccinia virus platform targeting refractory solid tumours
VacV Biotherapeutics is a cancer immunotherapy company developing engineered oncolytic Vaccinia virus-based therapeutics for the treatment of solid tumours. Spun out of Barts Cancer Institute and Queen Mary University of London, the company's platform uses a modified Vaccinia virus to simultaneously destroy tumour…